Targeting IL-1β in the Treatment of Atherosclerosis
The role of inflammation in atherosclerosis has been recognized several decades ago and existing treatments provide benefits in part through non-specific anti-inflammatory actions. Compared with other cytokines, interleukin-1β (IL-1β) is associated with acute and chronic inflammation. Anti-inflammat...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2020.589654/full |
| _version_ | 1818925973839544320 |
|---|---|
| author | Wuqian Mai Wuqian Mai Yuhua Liao Yuhua Liao |
| author_facet | Wuqian Mai Wuqian Mai Yuhua Liao Yuhua Liao |
| author_sort | Wuqian Mai |
| collection | DOAJ |
| description | The role of inflammation in atherosclerosis has been recognized several decades ago and existing treatments provide benefits in part through non-specific anti-inflammatory actions. Compared with other cytokines, interleukin-1β (IL-1β) is associated with acute and chronic inflammation. Anti-inflammatory therapy with canakinumab targeting the IL-1β innate immunity pathway could significantly reduce the rate of recurrent cardiovascular events than placebo. The results of CANTOS suggested an important role of IL-1β in atherosclerosis. However, there are numerous mechanisms that are to be clarified. We herein discussed the important immunomodulatory effect IL-1β exerts on atherosclerosis and the potential mechanisms underlying it. We also reviewed bench-to-bedside clinical translation of IL-1β neutralizing strategies associated with the use of IL-1β blockade in patients with atherosclerosis. |
| first_indexed | 2024-12-20T02:49:44Z |
| format | Article |
| id | doaj.art-6be24e7f8d7a4f9a93a9ccdeb1b184b4 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-20T02:49:44Z |
| publishDate | 2020-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-6be24e7f8d7a4f9a93a9ccdeb1b184b42022-12-21T19:56:05ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-12-011110.3389/fimmu.2020.589654589654Targeting IL-1β in the Treatment of AtherosclerosisWuqian Mai0Wuqian Mai1Yuhua Liao2Yuhua Liao3Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaKey Lab of Molecular Biological Targeted Therapies of the Ministry of Education, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaKey Lab of Molecular Biological Targeted Therapies of the Ministry of Education, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaThe role of inflammation in atherosclerosis has been recognized several decades ago and existing treatments provide benefits in part through non-specific anti-inflammatory actions. Compared with other cytokines, interleukin-1β (IL-1β) is associated with acute and chronic inflammation. Anti-inflammatory therapy with canakinumab targeting the IL-1β innate immunity pathway could significantly reduce the rate of recurrent cardiovascular events than placebo. The results of CANTOS suggested an important role of IL-1β in atherosclerosis. However, there are numerous mechanisms that are to be clarified. We herein discussed the important immunomodulatory effect IL-1β exerts on atherosclerosis and the potential mechanisms underlying it. We also reviewed bench-to-bedside clinical translation of IL-1β neutralizing strategies associated with the use of IL-1β blockade in patients with atherosclerosis.https://www.frontiersin.org/articles/10.3389/fimmu.2020.589654/fullIL-1βatherosclerosisclinical trialsimmune systeminflammationtherapy |
| spellingShingle | Wuqian Mai Wuqian Mai Yuhua Liao Yuhua Liao Targeting IL-1β in the Treatment of Atherosclerosis Frontiers in Immunology IL-1β atherosclerosis clinical trials immune system inflammation therapy |
| title | Targeting IL-1β in the Treatment of Atherosclerosis |
| title_full | Targeting IL-1β in the Treatment of Atherosclerosis |
| title_fullStr | Targeting IL-1β in the Treatment of Atherosclerosis |
| title_full_unstemmed | Targeting IL-1β in the Treatment of Atherosclerosis |
| title_short | Targeting IL-1β in the Treatment of Atherosclerosis |
| title_sort | targeting il 1β in the treatment of atherosclerosis |
| topic | IL-1β atherosclerosis clinical trials immune system inflammation therapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2020.589654/full |
| work_keys_str_mv | AT wuqianmai targetingil1binthetreatmentofatherosclerosis AT wuqianmai targetingil1binthetreatmentofatherosclerosis AT yuhualiao targetingil1binthetreatmentofatherosclerosis AT yuhualiao targetingil1binthetreatmentofatherosclerosis |